This record was last updated April 13, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-24.